知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

6060 records (took 0.041 seconds)

    Tissue-selective insulin analogs
    2.
    发明授权
    Tissue-selective insulin analogs 失效
    组织选择性胰岛素类似物

    公开(公告)号：US5268453A

    公开(公告)日：1993-12-07

    申请号：US918953

    申请日：1992-07-30

    Applicant: Robin J. Andy ,  Eric R. Larson

    Inventor： Robin J. Andy ,  Eric R. Larson

    IPC: A61K38/00 ,  C07K14/62 ,  C07K7/00 ,  A61K37/26 ,  C12P21/06

    CPC classification number: C07K14/62 ,  A61K38/00 ,  Y10S514/866

    Abstract: Human insulin analogs are disclosed. These analogs are tissue-selective. Accordingly, pharmaceutical formulations containing the analogs of the invention provide superior clinical benefits as compared to human insulin when used in the treatment of patients suffering from diabetes. The analogs are modified at amino residue A12, A15 or A19, are different from the naturally occurring residue at said position, and are hepatoselective. Also disclosed are human insulin analogs modified at amino acid residues A12 or A14 or amino acid residues A10 and A13 different from naturally occurring residues or residues at said position or positions and are peripheral selective. DNA sequences and microorganisms comprising sequences coding for human insulin analogs are also provided. Processes for preparing the human insulin analogs are described.

    Abstract translation: 人胰岛素类似物被公开。 这些类似物是组织选择性的。 因此，当用于治疗患有糖尿病的患者时，与人胰岛素相比，含有本发明类似物的药物制剂提供了优异的临床益处。 类似物在氨基残基A12，A15或A19处被修饰，与所述位置处的天然存在的残基不同，并且是肝选择性的。 还公开了在氨基酸残基A12或A14处修饰的人胰岛素类似物或在所述位置或位置处与天然存在的残基或残基不同的氨基酸残基A10和A13，并且是周边选择性的。 还提供了包含编码人胰岛素类似物的序列的DNA序列和微生物。 描述了制备人胰岛素类似物的方法。

    BLISTER PACKAGING FOR PHARMACEUTICALS
    4.
    发明申请
    BLISTER PACKAGING FOR PHARMACEUTICALS 有权

    公开(公告)号：US20250041159A1

    公开(公告)日：2025-02-06

    申请号：US18717689

    申请日：2022-12-16

    Applicant: PFIZER INC.

    Inventor： Thomas HUBER ,  Hetal NAIK

    IPC: A61J1/03 ,  B65D75/36

    Abstract: A blister package is disclosed herein. The blister package includes a body, a plurality of pockets, and a top seal. The body has a top surface and a bottom surface opposite the top surface. The plurality of pockets is formed in the body. Each of the plurality of pockets extend below the top surface of the body. Each pocket of the plurality of pockets is configured to hold a pharmaceutical. The plurality of pockets is arranged in a manner that defines at least one dose. The plurality of pockets for the at least one dose includes a first pocket in parallel with a second pocket, and a third pocket perpendicular to the first pocket and the second pocket. The top seal is configured to interface with the body. The top seal is configured to hold the pharmaceutical in each respective pocket.

Patent Agency Ranking